In August of 2019 the the Cutaneous Lymphoma Foundation's Research Advisory Council, with support from the Leukemia & Lymphoma Society (LLS), launched the all new Cutaneous Lymphoma Catalyst Research Grant. The Catalyst grant will provide researchers with the funding needed to continue and/or complete their work being done in cutaneous lymphoma. This short-term research program will span two years and award two (or more depending on funding) $50,000 grants per year.
Cutaneous Lymphoma Catalyst Research Grant Recipients
Patrizia Fuschiotti, PhD, University of Pittsburgh
Michael Girardi, MD, Yale University School of Medicine
Ali Jabbari, MD, PhD, University of Iowa Carver College of Medicine
Xiaolong Zhou, MD, MSc, Northwestern University Feinberg School of Medicine
In March 2012, the Cutaneous Lymphoma Foundation’s Board of Directors approved a new Research Awards Program (RAP), the first dedicated exclusively to funding cutaneous lymphoma research. The signature funding initiative of the RAP, was the CLARIONS Grant Program, which stands for Curing Cutaneous Lymphoma by Advancing Research, Innovation and Offering New Solutions. This research grant program supported investigators interested in conducting innovative cutaneous lymphoma research.
CLARIONS Grant Recipients
Leandro Cerchietti, MD, Weill Cornell Medical College
Rachael Clark, MD, PhD, Brigham and Women's Hospital
Patrizia Fuschiotti, PhD, University of Pittsburgh
Sergei Koralov, PhD, New York University School of Medicine
Tae Jin Kim, PhD, Stanford University School of Medicine
John O'Malley, MD, PhD, Brigham and Women's Hospital
Delphine Rolland, PharmD, PhD, University of Pennsylvania
Stefan M. Schieke, MD, Medical College of Wisconsin
Learn more about CLARIONS recipients research in our annual Research Reports.
Research Discovers CTCL Incidence Rising in United States
The Cutaneous Lymphoma Foundation funded an important epidemiology study that shows that the number of new cases of CTCL has doubled. In this study, Drs. Vincent Criscione and Martin Weinstock of Brown University report that there are approximately 1,600 new cases of CTCL diagnosed each year in the United States. This represents over double the number of new cases in the past fifteen years.
Groundbreaking Quality of Life Research Study
Dr. Marie-France Demierre of Boston University School of Medicine, Director of Skin Oncology, collaborated with the Cutaneous Lymphoma Foundation on an extremely important study, that of our patients’ health-related quality of life. Health-related quality of life is a multidimensional term that includes the physical, functional, psychological, social health, and well-being of the individual.
Epidemiology Characterization Synonyms CTCL
BACKGROUND: The familial occurrence of mycosis fungoides (MF) has been reported only in 8 families. Recently, the HLA class II alleles DRB1* 11 and DQB1* 03 have been found to be significantly increased for patients with sporadic MF, suggesting a possible immunogenetic basis for the pathogenesis of this malignancy.
OBJECTIVE: We sought to detect familial occurrences of MF, to describe familial features, and to investigate the possible association or linkage with the HLA system in such cases.